Biogen’s Tau-Targeting Drug Shows Cognitive Benefit in Early Alzheimer’s Study — Ionis Pharmaceuticals, Inc.

Event summary

Biogen’s Phase 2 CELIA study of diranersen (BIIB080) showed cognitive benefits and reduced tau pathology in early Alzheimer’s patients.
The 60 mg dose every 24 weeks demonstrated the most significant slowing of clinical decline.
Diranersen did not meet its primary endpoint of dose response for CDR-SB change at Week 76.
Biogen plans to advance diranersen to registrational development based on the Phase 2 data.

The big picture

The CELIA study results position diranersen as a potential breakthrough in Alzheimer’s treatment, targeting tau pathology—a key driver of neurodegeneration. This success underscores the growing importance of antisense oligonucleotide therapies in neurology, with Ionis and Biogen leading the charge. The findings could reshape the competitive dynamics in the Alzheimer’s space, particularly as other tau-directed therapies struggle to show similar cognitive benefits.

What we're watching

Regulatory Pathway: Whether the FDA will expedite diranersen’s approval given the Fast Track designation and compelling Phase 2 data.
Clinical Validation: How the cognitive benefits observed in the CELIA study will translate into long-term efficacy in later-stage trials.
Competitive Landscape: The pace at which Biogen and Ionis can differentiate diranersen from other tau-targeting therapies in development.